Angiostasis as a way to improve immunotherapy

Thrombosis and Haemostasis

Volumn 101, Issue 6, 2009, Pages 1025-1031

  Griffioen, Arjan W ^a,b   Vyth Dreese, Florry A ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Adhesion molecules; Angiogenesis and inhibitors; Immunity

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ALPHA INTERFERON; ANGINEX; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIN; AXITINIB; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CETUXIMAB; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DNA VACCINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR; ERLOTINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 21; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; CELL ADHESION MOLECULE; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIGEN RECOGNITION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; COLON CANCER; CONFERENCE PAPER; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG FORMULATION; DRUG MEGADOSE; DRUG TARGETING; EFFECTOR CELL; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KIDNEY CARCINOMA; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; VACCINATION; ANIMAL; CELL ADHESION; CELLULAR IMMUNITY; DRUG COMBINATION; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NETHERLANDS; PATHOLOGY; TUMOR ESCAPE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION; CELL ADHESION MOLECULES; DRUG THERAPY, COMBINATION; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NETHERLANDS; TUMOR ESCAPE;

EID: 67049134054     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-08-0552     Document Type: Conference Paper

References (76)

1. Reis e Sousa C. Dendritic cells in a mature age. Nature reviews 2006; 6: 476-483.
2. Keller AM, Borst J. Control of peripheral T cell survival: a delicate division of labor between cytokines and costimulatory molecules. Human Immunol 2006; 67: 469-477. (Pubitemid 43765605)
3. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007; 13: 5256-5261. (Pubitemid 47510348)
4. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Ann Rev Immunol 2007; 25: 267-296. (Pubitemid 46697910)
5. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594-607. (Pubitemid 43290336)
6. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936. (Pubitemid 43093958)
7. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
8. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237-268. (Pubitemid 30368433)
9. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364. (Pubitemid 26272076)
10. Molema G, Griffioen AW. Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Immunol Today 1998; 19: 392-394. (Pubitemid 28389700)
11. Griffioen AW, Damen CA, Martinotti S, et al. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996; 56: 1111-1117. (Pubitemid 26065408)
12. Nooijen PT, Westphal JR, Eggermont AM, et al. Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am J Pathol 1998; 152: 679-682. (Pubitemid 28110714)
13. Griffioen AW, Damen CA, Blijham GH, et al. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 1996; 88: 667-673. (Pubitemid 26240398)
14. Melder RJ, Koenig GC, Witwer BP, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996; 2: 992-997. (Pubitemid 26306837)
15. Dirkx AE, Oude Egbrink MG, Kuijpers MJ, et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 2003; 63: 2322-2329. (Pubitemid 36538644)
16. Hellwig SM, Damen CA, van Adrichem NP, et al. Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors. Cancer Lett 1997; 120: 203-211. (Pubitemid 27496818)
17. Hellebrekers DM, Jair KW, Vire E, et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 2006; 5: 467-475.
18. Hellebrekers DM, Castermans K, Vire E, et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 2006; 66: 10770-10777. (Pubitemid 44876972)
19. Hellebrekers DM, Melotte V, Vire E, et al. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 2007; 67: 4138-4148. (Pubitemid 46815059)
20. Flati V, Pastore LI, Griffioen AW, et al. Endothelial cell anergy is mediated by bFGF through the sustained activation of p38-MAPK and NF-eb inhibition. Int J Immunopathol Pharmacol 2006; 19: 761-773. (Pubitemid 46145040)
21. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964. (Pubitemid 44498003)
22. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213. (Pubitemid 36077915)
23. Baeten CI, Castermans K, Hillen HF, et al. Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer. Clin Gastroenterol Hepatol 2006; 4: 1351-1357. (Pubitemid 44716741)
24. Sun X, Kanwar JR, Leung E, et al. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Ther 2001; 8: 719-727. (Pubitemid 32983128)
25. Sun X, Krissansen GW, Fung PW, et al. Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver. Int J Cancer 2005; 113: 670-677. (Pubitemid 40038746)
26. Cirone P, Bourgeois JM, Shen F, et al. Combined immunotherapy and antiangiogenic therapy of cancer with microencapsulated cells. Human Gene Ther 2004; 15: 945-959. (Pubitemid 39372571)
27. Dirkx AE, Oude Egbrink MG, Castermans K, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. Faseb J 2006; 20: 621-630. (Pubitemid 44933306)
28. Gyorffy S, Palmer K, Podor TJ, et al. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. J Immunol 2001; 166: 6212-6217. (Pubitemid 32440752)
29. Li M, Huang X, Zhu Z, et al. The therapeutic efficacy of angiostatin against weakly- and highly-immunogenic 3LL tumors. In vivo (Athens, Greece) 2002; 16: 577-582. (Pubitemid 35460372)
30. Romagnani P, Lasagni L, Annunziato F, et al. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 2004; 25: 201-209. (Pubitemid 38372168)
31. Addison CL, Arenberg DA, Morris SB, et al. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Human Gene Ther 2000; 11: 247-261. (Pubitemid 30080383)
32. Sharma S, Stolina M, Luo J, et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000; 164: 4558-4563. (Pubitemid 30238052)
33. Strieter RM, Belperio JA, Burdick MD, et al. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann NY Acad Sci 2004; 1028: 351-360. (Pubitemid 40361836)
34. Tromp SC, oude Egbrink MG, Dings RP, et al. Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int Immunol 2000; 12: 671-676.
35. Griffioen AW, Damen CA, Mayo KH, et al. Angiogenesis inhibitors overcome tumor induced endothelial cell anergy. Int J Cancer 1999; 80: 315-319. (Pubitemid 29001738)
36. Budson AE, Ko L, Brasel C, et al. The angiogenesis inhibitor AGM-1470 selectively increases E-selectin. Biochem Biophys Res Commun 1996; 225: 141-145. (Pubitemid 26285409)
37. Zhang H, Issekutz AC. Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668. Am J Pathol 2002; 160: 2219-2230. (Pubitemid 34663412)
38. Luo J, Lin J, Paranya G, et al. Angiostatin upregulates E-selectin in proliferating endothelial cells. Biochem Biophys Res Commun 1998; 245: 906-911. (Pubitemid 28414016)
39. Dirkx AE, Oude Egbrink MG, Wagstaff J, et al. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 2006; 80: 1183-1196. (Pubitemid 44904956)
40. Leek RD, Lewis CE, Whitehouse R, et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996; 56: 4625-4629. (Pubitemid 26338061)
41. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113: 293-301.
42. Verra N, de Jong D, Bex A, et al. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. European Urol 2005; 48: 527-533. (Pubitemid 41188416)
43. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nature Rev 2006; 6: 595-601. (Pubitemid 44134092)
44. Skak K, Kragh M, Hausman D, et al. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov 2008; 7: 231-240.
45. Hong C, Park SH. Application of natural killer T cells in antitumor immunotherapy. Critical Rev Immunol 2007; 27: 511-525.
46. Tacken PJ, de Vries IJ, Torensma R, et al. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nature Rev 2007; 7: 790-802. (Pubitemid 47480309)
47. Bins AD, Jorritsma A, Wolkers MC, et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005; 11: 899-904. (Pubitemid 41161124)
48. Gattinoni L, Powell DJ, Jr., Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nature Rev 2006; 6: 383-393.
49. Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26: 332-342. (Pubitemid 36858717)
50. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129. (Pubitemid 44547756)
51. Schumacher TN. T-cell-receptor gene therapy. Nature Rev 2002; 2: 512-519. (Pubitemid 37328742)
52. Kessels HW, Wolkers MC, van den Boom MD, et al. Immunotherapy through TCR gene transfer. Nature Immunol 2001; 2: 957-961. (Pubitemid 32976169)
53. Jorritsma A, Bins AD, Schumacher TN, et al. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer. Cancer Res 2008; 68: 2455-2462.
54. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118: 1991-2001.
55. Begley J, Ribas A. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 2008; 14: 4385-4391.
56. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunological Rev 2008; 222: 357-368.
57. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 2008; 14: 2431-2436. (Pubitemid 351551077)
58. Bonehill A, Tuyaerts S, Van Nuffel AM, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 2008; 16: 1170-1180.
59. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007; 13: 5271-5279. (Pubitemid 47510350)
60. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005; 54: 307-314. (Pubitemid 40238924)
61. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nature Rev 2008; 8: 467-477. (Pubitemid 351733418)
62. Krambeck AE, Thompson RH, Dong H, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 2006; 103: 10391-10396. (Pubitemid 44051177)
63. Crispen PL, Sheinin Y, Roth TJ, et al. Tumor cell and tumor vasculature expression of b7-h3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008; 14: 5150-5157.
64. Perillo NL, Pace KE, Seilhamer JJ, et al. Apoptosis of T cells mediated by galectin-1. Nature 1995; 378: 736-739. (Pubitemid 26001948)
65. Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 2006; 103: 15975-15980. (Pubitemid 44657577)
66. Rabinovich GA, Baum LG, Tinari N, et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 2002; 23: 313-320.
67. Griffioen AW, van der Schaft DW, Barendsz-Janson AF, et al. Anginex, a designed peptide that inhibits angiogenesis. Biochem J 2001; 354: 233-242. (Pubitemid 32209858)
68. Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203: 871-881.
69. Haanen JB, van Oijen MG, Tirion F, et al. In situ detection of virus- and tumor-specific T-cell immunity. Nat Med 2000; 6: 1056-1060.
70. Vyth-Dreese FA, Kim YH, Dellemijn TA, et al. In situ visualization of antigen-specific T cells in cryopreserved human tissues. J Immunol Methods 2006; 310: 78-85.
71. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949. (Pubitemid 39273735)
72. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008; 111: 5610-5620.
73. Kepp O, Tesniere A, Zitvogel L, et al. The immunogenicity of tumor cell death. Current Opin Oncol 2009; 21: 71-76.
74. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203: 1259-1271. (Pubitemid 43736595)
75. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14: 5158-5165.
76. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.